Closed · RFA-CA-10-016 · CFDA 93.393;93.394;93.396;93.397 · Discretionary
Clinical Proteomic Technologies for Cancer Initiative (CPTC): Proteome Characterization Centers (U24)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- September 29, 2010
- Close date
- -
- Expected awards
The verdict
Clinical Proteomic Technologies for Cancer Initiative (CPTC): Proteome Characterization Centers (U24) is a closed discretionary listing from National Institutes of Health that offered Varies by applicant. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.
- Varies
- award range
- Closed
- application status
- 93.393;93.394;93.396;93.397
- CFDA program
- 12,419
- other opportunities from National Institutes of Health
Archived opportunity record
Clinical Proteomic Technologies for Cancer In… is closed (last close September 29, 2010). Check the agency catalog for replacement NOFOs. National Institutes of Health still indexes 12,419 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed September 29, 2010
Instrument
Cooperative Agreement
Description
Purpose. This Funding Opportunity Announcement (FOA) seeks to build upon the proteomic standards, technologies, standard operating procedures, workflows, and reproducibility of protein identification and quantification developed through the Clinical Proteomic Technologies for Cancer initiative (CPTC; http://proteomics.cancer.gov) by soliciting grant applications to build a multidisciplinary collaborative team of Proteome Characterization Centers (PCCs). The PCCs are expected to foster multi-institutional and transdisciplinary interactions using data and selected biospecimens from cancer genomics programs (e.g., The Cancer Genome Atlas [TCGA; http://cancergenome.nih.gov] and others) to systematically define the functional cancer proteome that derives from alterations in cancer genomes, discover and verify protein (and peptide) biomarkers, and in doing so, drive the development of proteomic technologies. Mechanism of Support. This FOA will utilize the NIH U24 cooperative agreement funding mechanism. Funds Available and Anticipated Number of Awards. For this FOA, the NCI has committed approximately $15 - $24 million in total costs in FY 2011, and $75 - $120 million over the planned 5-year project period, to support 6-8 center awards.
Market-open applicant set · includes for-profit door
The eligibility set for Clinical Proteomic Technologies for Cancer In… includes a for-profit door among 9 printed types (State governments; County governments; City or township governments; Public / state-controlled institutions of higher education; +5 more). Competitive traffic can include commercial applicants alongside other listed classes. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Education · Health (ED;HL). Only 4 other National Institutes of Health listings share this exact eligibility-code string (0% of 12,420).
- Code 00
- State governments
- Code 01
- County governments
- Code 02
- City or township governments
- Code 06
- Public / state-controlled institutions of higher education
- Code 12
- Nonprofits with 501(c)(3) status (other than IHEs)
- Code 13
- Nonprofits without 501(c)(3) status (other than IHEs)
- Code 20
- Private institutions of higher education
- Code 22
- For-profit organizations other than small businesses
- Code 25
- Others (see official listing text)
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
What to do next
Clinical Proteomic Technologies for Cancer In… is closed; use the parent program and agency catalog for the next funding cycle.
- Browse open federal opportunities in the same category when this listing is closed. Open opportunities
- Look up CFDA 93.393;93.394;93.396;93.397 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |